Health ImprOvement Program of Bone in China
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- Regular follow-up
- Study type
- Observational
- Intervention type
- other
- Primary sponsor
- Second Xiangya Hospital of Central South University
- Location
- Changsha, China
- Phase
- N/A
- Start date
- Feb 27, 2021
- End date
- Feb 27, 2031
- Enrollment
- 5000 participants
bone mineral density bone mineral density,Occurrence of fracture,clinical risk factors of osteoporotic fracture
Fracture risk factors have long been identified as key factors in osteoporosis and fragility
 fractures. The WHO recommended Fracture risk assessmenttool (FRAX) applies clinical risk
 factors to assess the absolute risk of osteoporotic fractures in each individual. Our
 preliminary study suggests that FRAX estimates may underestimate the risk of fractures in the
 Chinese population. In order to optimize the risk prediction model of osteoporotic fractures,
 a treatment threshold and its optimal cutting point were initially established based on the
 data of the health management Center of the Second Xiangya Hospital of Central South
 University.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05906147
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05906147 through Pure Global AI's free database. This phase not specified trial is sponsored by Second Xiangya Hospital of Central South University and is currently Recruiting. The study focuses on Osteoporosis. Target enrollment is 5000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.